ライフサイエンスコーパス: sarcopenia

1 [BMI] <20 kg/m(2)) or skeletal muscle mass (sarcopenia).

2 esis (inactivity), or an alteration in both (sarcopenia).

3 in the etiology of age-related muscle loss (sarcopenia).

4 s of body weight and loss of lean body mass (sarcopenia).

5 g skeletal muscle weakness in aging mammals (sarcopenia).

6 penia, and 14.4% vs. 8.4%, p = 0.002 for pre-sarcopenia).

7 with satellite cell senescence and premature sarcopenia.

8 ondrial disease, inflammatory myopathies and sarcopenia.

9 on to myofibre homeostasis to play a part in sarcopenia.

10 ogram and might therefore reduce the risk of sarcopenia.

11 nd therapeutic options for the management of sarcopenia.

12 uscle recovery may contribute to age-related sarcopenia.

13 ights into therapeutic targets for combating sarcopenia.

14 ect in muscle but instead leads to premature sarcopenia.

15 ge-induced loss of muscle mass and function, sarcopenia.

16 mic inflammation are all key contributors to sarcopenia.

17 cations for treating muscular dystrophies or sarcopenia.

18 and inflammation have potential for treating sarcopenia.

19 lated and most significantly correlated with sarcopenia.

20 s in available satellite cells and premature sarcopenia.

21 pment and testing of novel interventions for sarcopenia.

22 l muscle and has been recommended to prevent sarcopenia.

23 e useful for the prevention and treatment of sarcopenia.

24 ght therefore be useful for the treatment of sarcopenia.

25 s of oxidative damage and an acceleration of sarcopenia.

26 rial dysfunction are potential mechanisms of sarcopenia.

27 scle mass and strength, a condition known as sarcopenia.

28 ed, given the prevalence of osteoporosis and sarcopenia.

29 rly growth is poor have an increased risk of sarcopenia.

30 flammatory process and possibly the onset of sarcopenia.

31 stimuli may contribute to the development of sarcopenia.

32 Grip strength was used as a marker of sarcopenia.

33 important contributor to the development of sarcopenia.

34 n that appears to be mediated partly through sarcopenia.

35 the balance skewed in favor of catabolism in sarcopenia.

36 nt to avoid protein calorie malnutrition and sarcopenia.

37 ole in the age-related process that leads to sarcopenia.

38 ute a major proponent in the pathogenesis of sarcopenia.

39 nd IL-6 concentrations after adjustments for sarcopenia.

40 st in understanding the mechanisms of muscle sarcopenia.

41 ibility of pharmacologically enhancing it in sarcopenia.

42 ve deterioration of muscle, resembling human sarcopenia.

43 ated mitochondrial DNA deletion mutations in sarcopenia.

44 extent of the public health problem posed by sarcopenia.

45 op a method for estimating the prevalence of sarcopenia.

46 rly may actually reflect an association with sarcopenia.

47 al muscle and plays a key role in initiating sarcopenia.

48 s (T2DM) with the risk of sarcopenia and pre-sarcopenia.

49 d with increased risks of sarcopenia and pre-sarcopenia.

50 nctional decline with ageing, culminating in sarcopenia.

51 emic loss of muscle mass and function termed sarcopenia.

52 emerging as an effective countermeasure for sarcopenia.

53 nflammation was associated with at-diagnosis sarcopenia.

54 adults is a risk factor for muscle loss and sarcopenia.

55 f satellite cell activity is also a cause of sarcopenia.

56 nections between IIS, nutritional status and sarcopenia, a hallmark feature of aging in muscle.

57 Sarcopenia, a loss of muscle mass and strength, contribu

58 obesity did not confer any greater risk than sarcopenia alone.

59 Sarcopenia, along with intramuscular lipids, is associat

60 ic pathways show potential benefit to combat sarcopenia although further research is required, partic

61 iduals to acquired muscle disease, including sarcopenia and atrophy, although such studies are in the

62 ated skeletal muscle atrophy which occurs in sarcopenia and cachexia.

63 s conditions characterised by low LM such as sarcopenia and cachexia.

64 ets to prevent muscle wasting, in particular sarcopenia and cachexia.

65 ate process that increases susceptibility to sarcopenia and cardiovascular diseases.

66 ]i) movement may underlie the progression of sarcopenia and contractile dysfunction during muscle agi

67 eraction was found between either obesity or sarcopenia and CRP, IL-6, and PAI-1 concentrations.

68 healthy individuals, but their effect on the sarcopenia and fatigue associated with long-term dialysi

69 Sarcopenia and frailty predicted hospital length of stay

70 ); predictive ability did not differ between sarcopenia and frailty prediction model, reflected by ch

71 Sarcopenia and frailty were quantified in 102 patients a

72 and regenerative capacity, which can lead to sarcopenia and increased mortality.

73 Methods of estimating the prevalence of sarcopenia and its associated risks in elderly populatio

74 idered a therapeutic approach for preventing sarcopenia and maintaining physical independence in olde

75 Cirrhosis is characterized by sarcopenia and malnutrition, leading to progressive func

76 tential therapeutic approach for age-related sarcopenia and metabolic disease.

77 molecular changes that correlated best with sarcopenia and might contribute to its pathogenesis, we

78 Pathophysiological mechanisms relating sarcopenia and NASH may include insulin resistance (IR)

79 lore the complex inter-relationships between sarcopenia and NASH.

80 Patients with both sarcopenia and NLR of 3 or greater (vs neither) had doub

81 The effect of sarcopenia and obesity (defined as the percentage of fat

82 were 20 deaths among the 59 patients who had sarcopenia and only 7 deaths in the nonsarcopenic group.

83 tic computed tomography (CT) scans to assess sarcopenia and osteopenia as indicators of underlying fr

84 Among the 408 who survived to discharge, sarcopenia and osteopenia were associated with higher ri

85 74 were retrospectively diagnosed with both sarcopenia and osteopenia, 167 with sarcopenia only, 48

86 d loss of muscle and bone mass and resultant sarcopenia and osteopenia.

87 te the association of T2DM with the risks of sarcopenia and pre-sarcopenia in China.

88 The prevalence of sarcopenia and pre-sarcopenia was significantly higher i

89 2 diabetes mellitus (T2DM) with the risk of sarcopenia and pre-sarcopenia.

90 ificantly associated with increased risks of sarcopenia and pre-sarcopenia.

91 te cells neither accelerated nor exacerbated sarcopenia and that satellite cells did not contribute t

92 xercise is the only known strategy to combat sarcopenia and this is largely mediated through improvem

93 To determine whether sarcopenia and/or osteopenia are associated with 1-year

94 Sarcopenia and/or osteopenia, assessed via total cross-s

95 2014 were analyzed to identify patients with sarcopenia and/or osteopenia.

96 xperience malnutrition, reduced muscle mass (sarcopenia), and fatigue for which no effective treatmen

97 thy controls (14.8% vs. 11.2%, p = 0.035 for sarcopenia, and 14.4% vs. 8.4%, p = 0.002 for pre-sarcop

98 of cancer, cognitive decline, osteoporosis, sarcopenia, and affective disorders, are the world's big

99 Cachexia, sarcopenia, and atrophy due to inactivity are characteri

100 ood, clinical interventions for weight loss, sarcopenia, and cytokine alterations have been used with

101 ther causes of weight loss include anorexia, sarcopenia, and dehydration.

102 stic systemic inflammation with at-diagnosis sarcopenia, and determine whether these factors interact

103 of age-related muscle wasting, also known as sarcopenia, and discusses critical areas of uncertainty

104 thora of diseases including cancer cachexia, sarcopenia, and muscular dystrophy.

105 higher protein intake on weight management, sarcopenia, and other physiologic functions, efforts sho

106 xide disarrays, renal interstitial fibrosis, sarcopenia, and worsening proteinuria and kidney functio

107 Systemic inflammation and sarcopenia are easily evaluated, predict mortality in ma

108 The age-related mechanisms underlying sarcopenia are largely unknown.

109 consumed at each meal as a countermeasure to sarcopenia are presented and discussed.

110 The mechanisms underlying sarcopenia are unclear and the development of optimal th

111 Sarcopenia assessed by ultrasound may be utilized as rap

112 ed by ultrasound and the predictive value of sarcopenia at SICU admission for adverse outcome has not

113 as defined using the Asian Working Group for Sarcopenia (AWGS) criteria that include both muscle mass

114 These rats exhibit sarcopenia beginning at 21 months.

115 key regulator of muscle fiber atrophy during sarcopenia but may play a key role in the decline of mit

116 There are no approved therapies for sarcopenia, but the antihypertrophic myokine myostatin i

117 Bedside diagnosis of sarcopenia by ultrasound predicts adverse discharge disp

118 equence of many primary conditions including sarcopenia, cachexia, osteoporosis, HIV/AIDS, and chroni

119 Sarcopenia can be quantified by ultrasound and the predi

120 velop a premature aging phenotype, including sarcopenia, cardiomyopathy and decreased lifespan.

121 arious symptoms of premature aging including sarcopenia, cataracts, less subcutaneous fat, organ shri

122 Sarcopenia combined with inflammation nearly doubled ris

123 Assessment of sarcopenia could be used to evaluate patients before hep

124 Understanding the mechanisms that govern sarcopenia (depletion of muscle mass with age) may sugge

125 Age-related sarcopenia describes the loss of muscle strength and oft

126 expression and suggests a mechanism by which sarcopenia develops in cirrhotic patients.

127 Sarcopenia did not impact disease-specific (P = 0.14) or

128 of skeletal muscle mass occurs during aging (sarcopenia), disease (cachexia), or inactivity (atrophy)

129 ation analysis identified gene signatures of sarcopenia distinct from gene signatures of aging.

130 accumulation is postulated to play a role on sarcopenia during aging, which is believed to be due alt

131 motor neurons plays a key role in initiating sarcopenia during aging.

132 ssociated with protein-energy wasting (PEW), sarcopenia, dynapenia, and other complications of CKD.

133 In view to preventing sarcopenia, elderly subjects should be advised to favor

134 m midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of ind

135 olism, and muscle loss, for instance, during sarcopenia, has profound consequences.

136 sms by which oxidative stress contributes to sarcopenia have not been thoroughly investigated.

137 Increasing NLR was associated with sarcopenia in a dose-response manner (compared with NLR

138 ts increasingly rapid progression results in sarcopenia in a subset of individuals.

139 was performed to determine the mechanisms of sarcopenia in alcoholic cirrhosis and potential reversal

140 SUMMARY OF BACKGROUND DATA: Sarcopenia in cancer may confer negative outcomes, but i

141 as well as sarcomere disruption and striking sarcopenia in cardiac and skeletal muscle, a classical f

142 of T2DM with the risks of sarcopenia and pre-sarcopenia in China.

143 sues that often occurs after surgery or with sarcopenia in late-stage cancer.

144 protein may be a modifiable risk factor for sarcopenia in older adults and should be studied further

145 ribute to the development and progression of sarcopenia in older adults.

146 ght loss, even with regain, could accelerate sarcopenia in older adults.

147 We will discuss the impact of sarcopenia in patients with NASH and therapeutic options

148 nction, motor coordination and resistance to sarcopenia in rhesus monkeys have recently been reported

149 effect of early-onset calorie restriction on sarcopenia in the aging rat.

150 to study the prevalence and significance of sarcopenia in the multimodal management of locally advan

151 centrations are associated with muscle loss (sarcopenia) in the elderly.

152 Sarcopenia increased (P = 0.02) from 16% at diagnosis to

153 Sarcopenia increases through multimodal therapy, is asso

154 An NLR of 3 or greater and sarcopenia independently predicted overall (hazard ratio

155 was significantly lower on those with higher sarcopenia index (-1 d for each 10 unit of sarcopenia in

156 r sarcopenia index (-1 d for each 10 unit of sarcopenia index [95% CI, -1.4 to -0.2; p = 0.006]).

157 The relationship between sarcopenia index and hospital and 90-day mortality, and

158 The correlation (r) between sarcopenia index and muscle mass was 0.62 and coefficien

159 The sarcopenia index is a fair measure for muscle mass estim

160 rpose of this study was to describe a simple sarcopenia index using routinely available renal biomark

161 Evaluation III, body surface area, and age, sarcopenia index was independently predictive of both ho

162 Sarcopenia is a complex multifactorial process, some of

163 Sarcopenia is a complex, multifactorial process facilita

164 Sarcopenia is a condition characterized by progressive a

165 Sarcopenia is a debilitating condition afflicting the el

166 Sarcopenia is a hallmark of functional compromise.

167 Recent studies have shown that sarcopenia is a novel risk factor for developing NAFLD.

168 Sarcopenia is an important risk factor for falls, but it

169 Sarcopenia is associated with a poor prognosis in the IC

170 Sarcopenia is associated with loss of independence and i

171 Sarcopenia is associated with loss of strength and funct

172 Sarcopenia is believed to be associated with metabolic,

173 Sarcopenia is defined as a progressive and generalized l

174 Irrespective of how sarcopenia is defined, both low muscle mass and poor mus

175 ugh no consensus diagnosis has been reached, sarcopenia is increasingly defined by both loss of muscl

176 ween the liver and skeletal muscle mediating sarcopenia is not well understood.

177 line of growth hormone in the development of sarcopenia is one of many factors, and its etiologic rol

178 Sarcopenia is thought to be accompanied by increased mus

179 Although the etiology of sarcopenia is unknown, the correlation during aging betw

180 Skeletal muscle loss (sarcopenia) is a major clinical complication in alcoholi

181 ted loss of muscle mass and function, termed sarcopenia, is a catastrophic process, which impacts sev

182 This condition, termed sarcopenia, is a major cause of falls and of the subsequ

183 Loss of muscle mass, or sarcopenia, is nearly universal in cirrhosis and adverse

184 icle is to review the current definitions of sarcopenia, its potential causes and clinical consequenc

185 The combination of inflammation and sarcopenia may be able to identify patients with early-s

186 and imaging to assess muscle mass to detect sarcopenia, may provide insight into the likelihood of t

187 erformance Battery (SPPB) and Short Portable Sarcopenia Measure (SPSM).

188 erformance Battery (SPPB) and Short Portable Sarcopenia Measure (SPSM).

189 tionnaire (Groningen Frailty Indicator), and sarcopenia measurement (L3 muscle index) can accurately

190 ls and in glucocorticoid-induced atrophy and sarcopenia of aging.

191 rolonged ammonia-lowering therapy to reverse sarcopenia of cirrhosis.

192 -1) and to explore the effect of obesity and sarcopenia on CRP, IL-6, and PAI-1 concentrations.

193 ith both sarcopenia and osteopenia, 167 with sarcopenia only, 48 with osteopenia only, and 161 with n

194 rtebral level, compared with a group with no sarcopenia or osteopenia.

195 Sarcopenia or skeletal muscle loss is a frequent, potent

196 M exhibited significantly increased risks of sarcopenia (OR = 1.37, 95% CI = 1.02-2.03) and pre-sarco

197 enia (OR = 1.37, 95% CI = 1.02-2.03) and pre-sarcopenia (OR = 1.73, 95% CI = 1.10-2.83) compared to n

198 is the relationship between low muscle mass (sarcopenia) or sarcopenic obesity and cancer prognosis?

199 Sarcopenia, or skeletal muscle atrophy, is a debilitatin

200 A new field of study is investigating sarcopenia, or skeletal muscle loss, in very old populat

201 PURPOSE OF REVIEW: Sarcopenia, or the decline of skeletal muscle tissue wit

202 Muscle mass decreases with age, leading to "sarcopenia," or low relative muscle mass, in elderly peo

203 f of older trauma patients in this study had sarcopenia, osteopenia, or both.

204 ignificantly associated with greater odds of sarcopenia, overfat, and sarcopenic obesity in women, bu

205 Sarcopenia predicted adverse discharge disposition (disc

206 Weight loss combined with sarcopenia presented the greatest risk of mortality.

207 The term sarcopenia refers to the loss of muscle mass that occurs

208 ion patency (providing molecular evidence of sarcopenia-related functional denervation and neuromuscu

209 Although the mechanisms underlying sarcopenia remain unclear, the skeletal muscle stem cell

210 hs capture increased abdominal adiposity and sarcopenia, respectively.

211 al muscle function, due to injury and aging (sarcopenia), results in a significantly decreased qualit

212 At 1 year, 35% had sarcopenia, significantly associated with pre-treatment

213 th physical activity, may delay the onset of sarcopenia, slow its progression, reduce the magnitude o

214 high Groningen Frailty Indicator score, and sarcopenia strongly predicted sepsis (P = 0.001; odds ra

215 2-/- muscles exhibited features of premature sarcopenia, such as selective type II fast fiber atrophy

216 e mass (osteopenia) and loss of muscle mass (sarcopenia) that occur with age are closely related.

217 A key determinant of geriatric frailty is sarcopenia, the age-associated loss of skeletal muscle m

218 ute to the fiber atrophy and loss that cause sarcopenia, the age-related decline of muscle mass and f

219 Molecular mechanisms underlying sarcopenia, the age-related loss of skeletal muscle mass

220 Sarcopenia, the loss of muscle mass and strength during

221 ty predicted higher survival rates only when sarcopenia was absent.

222 In a multivariate Cox regression model, sarcopenia was an independent predictor of higher mortal

223 Sarcopenia was assessed using the L3 muscle index utiliz

224 On multivariable analysis, preoperative sarcopenia was associated with CCI (P = 0.043), and CDC

225 Sarcopenia was defined as appendicular skeletal muscle m

226 Pre-sarcopenia was defined as having low skeletal muscle ind

227 Sarcopenia was defined as less than 52 cm2/m2 and less t

228 Sarcopenia was defined by computed tomography (CT) at L3

229 Sarcopenia was defined using the Asian Working Group for

230 Sarcopenia was diagnosed by ultrasound measurement of re

231 Sarcopenia was found to be a strong and independent prog

232 On multivariate analysis, sarcopenia was found to be an independent predictor of p

233 The relation of inflammation with sarcopenia was not independent of any of the considered

234 Sarcopenia was not predictive for anastomotic leakage or

235 Sarcopenia was significantly associated with self-report

236 The prevalence of sarcopenia and pre-sarcopenia was significantly higher in T2DM patients tha

237 Low muscle mass (sarcopenia) was defined as fat-free mass index (fat-free

238 An NLR of 3 or greater and sarcopenia were common (1133 [46%] and 1078 [44%], respe

239 cation of specific pathways of importance to sarcopenia will have relevance to a wide range of wastin

240 as the progression of muscular dystrophy and sarcopenia, yet the mechanisms underlying the change in